Physician profile
Jeffrey S Ehrlich
NPI 1972568863
$1,092.83
in general payments reported to CMS, 2019-2025
23 companies · $68.44 in 2025
The $68.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $12.77 · 2021: $288 · 2022: $240 · 2023: $133 · 2024: $100 · 2025: $68.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $349.10 | 2019-2025 | |
| Amgen INC. | $154.35 | 2019-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $70.60 | 2021-2022 | |
| Lilly USA, LLC | $70.35 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $69.93 | 2019-2023 | Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $38.43 | 2019-2022 | |
| Abbott Laboratories | $36.96 | 2021 | |
| Astellas Pharma US INC | $34.94 | 2019-2020 | |
| Novo Nordisk INC | $30.07 | 2022-2023 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $28.24 | 2021 | |
| Esperion Therapeutics, INC. | $21.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.73 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.82 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.06 | 2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.81 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $15.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.27 | 2024 | Eliquis |
| Glaxosmithkline, LLC. | $14.71 | 2023 | Rotarix, Bexsero |
| Kowa Pharmaceuticals America, INC. | $14.29 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.13 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.